NEW YORK (GenomeWeb News) - Cerep today said that it has signed an agreement with Eli Lilly & Co. covering the use of its kinase assay platform to study undisclosed drug targets.

The agreement is an extension of an existing deal between the two companies for access to Cerep's GPCR screening portfolio.

Cerep's kinase profiling service is based on PerkinElmer's Lance Ultra kinase assay technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.